12 November 2019 in Frontiers in Microbiology
Phage therapy requires libraries of well-characterized phages. Here we describe the generation of phage libraries for three target species: Escherichia coli, Pseudomonas aeruginosa, and Enterobacter cloacae. The basic phage characteristics on the isolation host, sequence analysis, growth properties, and host range and virulence on a number of contemporary clinical isolates are presented. This information is required before phages can be added to a phage library for potential human use or sharing between laboratories for use in compassionate use protocols in humans under eIND (emergency investigational new drug). Clinical scenarios in which these phages can potentially be used are discussed. The phages presented here are currently being characterized in animal models and are available for eINDs.
1 June 2020 in PHAGE: Therapy, Applications, and Research
Mutation is the most powerful driver of change for life on Earth. Pathogenic bacteria utilize mutation as a means to survive strong live-die selective pressures generated by chemical antibiotics. As such, the traditional drug-making pipeline, characterized by significant financial and time investment, is insufficient to keep pace with the rapid evolution of bacterial resistance to structurally fixed and chemically unmalleable antibacterial compounds. In contrast, the genetic diversity and adaptive mutability of the bacteriophage can be leveraged to not only overcome resistance but also used for the development of enhanced traits that increase lytic potential and therapeutic efficacy in relevant host microenvironments. This is the fundamental premise behind Baylor College of Medicine's Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR) initiative. In this perspective, we outline the concept, structure, and process behind TAILΦR's attempt to generate a personalized therapeutic phage that addresses the most clinically challenging of bacterial infections.
25 February 2014 in Aerosol Science and Technology
The performance of electrostatically charged blown microfiber filter media was characterized for high-volume sampling applications. Pressure drop and aerosol collection efficiency were measured at air pressures of 55.2 and 88.7 kilopascals (kPa) and filter face velocities ranging from 2.5 to 11.25 meters per second (m/s). Particle penetration was significant for particles above 0.5 micrometers (μm) in aerodynamic diameter where the onset of particle rebound was observed as low as 200 nanometers (nm). Particle retention was enhanced by treating filters in an aqueous solution of glycerol. Adding this retention agent eliminated electrostatic capture mechanisms but mitigated inertial rebound. Untreated filters had higher nanoparticle collection efficiencies at lower filter face velocities where electrostatic capture was still significant. At higher filter face velocities, nanoparticle collection efficiencies were higher for treated filters where inertial capture was dominant and particle rebound was mitigated. Significant improvements to microparticle collection efficiency were observed for treated filters at all air flow conditions. At high air pressure, filter efficiency was greater than 95% for particles less than 5 μm. At low air pressure, performance enhancements were not as significant since air velocities were significantly higher through the fiber mat. Measured single fiber efficiencies were normalized by the theoretical single fiber efficiency to calculate adhesion probability. The small fiber diameter (1.77 μm) of this particular filter gave large Stokes numbers and interception parameters forcing the single fiber efficiency to its maximum theoretical value. The adhesion probability was plotted as a function of the ratio of Stokes and interception parameter similar to the works of others. Single fiber efficiencies for inertial nanoparticle collection were compared to existing theories and correlations. Copyright 2014 American Association for Aerosol Research
8 September 2025 in International Journal of Antimicrobial Agents
Chronic urinary tract infections are persistent bacterial infections with the potential to drive antibiotic resistance. Like other persistent bacterial infections, intracellular bacterial reservoirs and biofilm formation hinder the clearance of pathogens despite long courses of antibiotic therapy. New strategies for treatment of these persistent infections are needed. Here we describe the results of an open-label individual patient study using bacteriophage therapy to treat a chronic urinary tract infection in an immunocompetent 72-year-old woman without underlying urolithiasis or indwelling devices. We co-administered HP3.1, HP3, and ES19 bacteriophages with demonstrated in vitro activity via bladder instillation, orally, and as a topical formulation. The primary outcome was safety and tolerability of the treatment. Adverse events were monitored through daily symptom logs and laboratory analysis of blood samples obtained throughout the study. We found that the treatment was safe and well tolerated with no serious adverse events reported. No adverse events were deemed related to the study material. The secondary outcomes were clinical and microbiological efficacy as monitored through daily symptom logs and standard urine culture, respectively. Two weeks after initial clinical improvement, her condition relapsed and culture was consistent with previous isolates. Treatment with ertapenem following bacteriophage therapy led to sustained clinical and microbiologic cure. Exploratory analysis through whole genome sequencing of pre- and post-treatment isolates identified mutations in genes associated with adhesion and evasion that may influence virulence and promote clearance. These results inform expanded randomized clinical trials and support the growing literature that bacteriophage therapies are safe and effective.